Evidence map›Paper›PMID 35891207›Full record

ArticleVaccines2022

Pathogenicity of

Melanie Caballero-Garcia, Alfredo Mendoza-Espinoza, Silvia Ascanio, Paula Chero, Rober Rojas, Yosef Daniel Huberman

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Microorganisms · 2026
    Review
  2. Research progress onFrontiers in microbiology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Melanie Caballero-GarciaResearch and Development, Quimtia S.A, Centro Ind. Las Praderas de Lurín Mza. B. Lote 1. Lima 16, Lurín CP 15823, Peru.
Alfredo Mendoza-EspinozaResearch and Development, Quimtia S.A, Centro Ind. Las Praderas de Lurín Mza. B. Lote 1. Lima 16, Lurín CP 15823, Peru.
Silvia AscanioResearch and Development, Quimtia S.A, Centro Ind. Las Praderas de Lurín Mza. B. Lote 1. Lima 16, Lurín CP 15823, Peru.
Paula CheroResearch and Development, Quimtia S.A, Centro Ind. Las Praderas de Lurín Mza. B. Lote 1. Lima 16, Lurín CP 15823, Peru.
Rober RojasResearch and Development, Quimtia S.A, Centro Ind. Las Praderas de Lurín Mza. B. Lote 1. Lima 16, Lurín CP 15823, Peru.
Yosef Daniel HubermanBacteriology, INTA EEA Balcarce, RN 226 Km 73, Balcarce CP 07620, Buenos Aires, Argentina.ORCID 0000-0001-5411-2997

Funding

ProCiencia 033-2019-Fondecyt-BM-INC.INV
6 · The paper itself

Abstract

Worldwide,

Indexed as

Avibacterium paragallinaruminfectious coryzapathogenicitypoultryvaccine

Identifiers

PMID35891207
PMCPMC9318190
OpenAlexW4283735778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.